Skip to content

US · MIST · BIOTECHNOLOGY

Milestone Pharmaceuticals Inc. (MIST) intrinsic value and stock valuation

$0.37as of 2026-11-21 · Mkt cap 98.34M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Milestone Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values MIST with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MIST’s statements →

Milestone Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Montreal, QC H4M 2X6 milestonepharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$1.55M
20172025
Net income
-$-63.06M
20172025
Free cash flow
-$-49.34M
20172025
Total equity
$41.8M-21.8% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$1.55M$0.00$1M$5M$15M
Operating income-$-62.48M-$-42.1M-$-61.1M-$-59.64M-$-43.07M
Net income-$-63.06M-$-41.52M-$-59.69M-$-58.39M-$-42.85M
EPSd-$-751.79K-$-667.42K-$-1.39M-$-1.38M-$-1.02M
Operating cash flow-$-49.04M-$-28.85M-$-46.42M-$-52.47M-$-33.22M
Capital expenditure-$-300K-$-30K-$-110K-$-270K$0.00
Free cash flow-$-49.34M-$-28.88M-$-46.54M-$-52.74M-$-33.22M
Total assets$113.6M$75.5M$75.2M$74.5M$119.9M
Total debt$58.4M$54.8M$51.8M$2.49M$700K
Net debt-$-14.67M$29.5M$38M-$-5.14M-$-113.44M
Total equity$41.8M$13.2M$16.8M$66.4M$112.6M
Cash and short-term investments$106M$69.7M$66M$64.6M$114.1M
Income statement
20252024202320222021
Revenue$1.55M$0.00$1M$5M$15M
Cost of revenue$110K$0.00$0.00$0.00$0.00
Gross profit$1.43M$0.00$1M$5M$15M
Research and development expenses$18.1M$14.4M$31.1M$39.8M$38.7M
Selling, general and administrative expenses$17.3M$27.8M$31.1M$24.8M$19.4M
Other expenses$28.5M$0.00$0.00$0.00$0.00
Operating expenses$63.9M$42.1M$62.1M$64.6M$58.1M
Cost and expenses$64M$42.1M$62.1M$64.6M$58.1M
Interest income$2.92M$4.16M$3.97M$1.25M$220K
Interest expense$3.84M-$-3.58M$2.55M$0.00$0.00
Depreciation and amortization$110K$100K$90K$90K$90K
Ebitda-$-59.45M-$-37.83M-$-57.04M-$-58.3M-$-42.76M
Operating income-$-62.48M-$-42.1M-$-61.1M-$-59.64M-$-43.07M
Total other income/expenses, net-$-920K$580K$1.41M$1.25M$220K
Income before tax-$-63.4M-$-41.52M-$-59.69M-$-58.39M-$-42.85M
Income tax expense-$-340K$0.00$0.00$0.00$0.00
Net income-$-63.06M-$-41.52M-$-59.69M-$-58.39M-$-42.85M
Weighted average shares outstanding$83.9M$62.2M$43M$42.5M$41.8M
Weighted average diluted shares outstanding$83.9M$62.2M$43M$42.5M$41.8M
Balance sheet
20252024202320222021
Cash and short-term investments$106M$69.7M$66M$64.6M$114.1M
Net receivables$3.51M$2.39M$3.85M$1.21M$480K
Inventory$650K$0.00$0.00$0.00$0.00
Total current assets$111.9M$73.9M$73M$71.8M$118.9M
Property, plant and equipment, net$1.64M$1.57M$2.19M$2.68M$930K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.64M$1.57M$2.19M$2.68M$930K
Total assets$113.6M$75.5M$75.2M$74.5M$119.9M
Accounts payable$5.64M$1.93M$3.98M$2.26M$4.38M
Short-term debt$650K$570K$550K$490K$220K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$14M$8.13M$7.23M$6.14M$6.78M
Long-term debt$57.7M$54.2M$51.2M$2M$470K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$57.8M$54.2M$51.2M$2M$470K
Capital lease obligations$540K$1.45M$2M$2M$470K
Total liabilities$71.8M$62.4M$58.5M$8.13M$7.25M
Common stock$352.6M$288.1M$260.5M$273.9M$251.9M
Retained earnings-$-430.6M-$-367.55M-$-326.03M-$-266.34M-$-206.32M
Accumulated other comprehensive income (loss)$55.7M$53.1M$48.5M$34.4M$51.3M
Total equity$41.8M$13.2M$16.8M$66.4M$112.6M
Total investments$32.9M$44.4M$52.2M$57M$0.00
Total debt$58.4M$54.8M$51.8M$2.49M$700K
Net debt-$-14.67M$29.5M$38M-$-5.14M-$-113.44M
Cash flow statement
20252024202320222021
Net income-$-63.06M-$-41.52M-$-59.69M-$-58.39M-$-42.85M
Depreciation and amortization$110K$100K$90K$90K$360K
Stock-based compensation$7.46M$5.78M$9.53M$9.05M$7.28M
Change in working capital$2.68M$3.66M$1.24M-$-3.26M$1.62M
Accounts receivable-$-1.12M$1.46M-$-2.64M-$-730K$100K
Inventory-$-650K$0.00$0.00$0.00$0.00
Accounts payable$4.43M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-49.04M-$-28.85M-$-46.42M-$-52.47M-$-33.22M
Investments in property, plant and equipment-$-300K-$-30K-$-110K-$-270K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$11.3M$8.28M$4.76M-$-57.12M$70M
Common stock issued$85.5M$27.3M$0.00$2.63M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$85.5M$32.1M$47.8M$3.09M$5.05M
Net change in cash$47.7M$11.6M$6.12M-$-106.5M$41.8M
Cash at end of period$73.1M$25.3M$13.8M$7.64M$114.1M
Operating cash flow-$-49.04M-$-28.85M-$-46.42M-$-52.47M-$-33.22M
Capital expenditure-$-300K-$-30K-$-110K-$-270K$0.00
Free cash flow-$-49.34M-$-28.88M-$-46.54M-$-52.74M-$-33.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Milestone Pharmaceuticals Inc.

        Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

        CEO
        Joseph G. Oliveto
        Employees
        38
        Beta
        0.97

        Explore

        Frequently asked questions

        What is the intrinsic value of Milestone Pharmaceuticals Inc. (MIST)?

        InvestorsCraft does not currently publish an intrinsic value for MIST. How the IC value is calculated.

        Is MIST undervalued?

        InvestorsCraft does not publish an undervaluation signal for MIST at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.